AlphaVax, Inc.
AlphaVax is a clinical-stage biopharmaceutical company developing innovative vaccines using its proprietary RNA particle alphavaccine vector platform. The company's mission is to redefine vaccines and their role in medicine by creating vaccines for infectious diseases, cancer immunotherapy, and biodefense applications. AlphaVax's vision is to advance vaccine technology through strategic partnerships, clinical trials, and a broad portfolio of vaccine candidates targeting various diseases and cancers.
Industries
Nr. of Employees
medium (51-250)
AlphaVax, Inc.
Not specified in the provided content.
Products
Pipeline of RNA replicon particle vaccine candidates
A portfolio of prophylactic and therapeutic vaccine candidates based on a self-replicating RNA replicon particle platform, advanced into multiple preclinical studies and Phase I/II clinical trials for infectious disease and oncology indications.
Pipeline of RNA replicon particle vaccine candidates
A portfolio of prophylactic and therapeutic vaccine candidates based on a self-replicating RNA replicon particle platform, advanced into multiple preclinical studies and Phase I/II clinical trials for infectious disease and oncology indications.
Services
Granting of licenses and collaborative development agreements to third parties and government agencies for specific disease or antigen applications of the RNA replicon vaccine platform.
Partnership-based development of prophylactic and therapeutic vaccine candidates with support for preclinical studies, clinical trial execution, immunomonitoring and regulatory interactions.
Granting of licenses and collaborative development agreements to third parties and government agencies for specific disease or antigen applications of the RNA replicon vaccine platform.
Partnership-based development of prophylactic and therapeutic vaccine candidates with support for preclinical studies, clinical trial execution, immunomonitoring and regulatory interactions.
Expertise Areas
- Vaccine platform development (self-replicating RNA replicons)
- Cancer immunotherapy vaccine development
- Infectious disease vaccine development
- Preclinical animal challenge studies
Key Technologies
- Self-replicating RNA replicon vectors
- Virus-like replicon particle (VRP) production
- Electroporation-mediated RNA delivery in cell lines
- Antigen expression from replicon RNA